High-Density Lipoprotein Metabolism

  • H. Bryan BrewerJr.


High-density lipoprotein (HDL) cholesterol concentrations are inversely associated with coronary heart disease (CHD) in humans [1,2]. The initial descriptions of this inverse relationship in the early 1950s [3–5] were “rediscovered” in the 1970s [6–9]. The major mechanism proposed for the protective effect of HDL is reverse cholesterol transport, a process in which excess cholesterol from peripheral cells is transported back to the liver for removal from the body [10]. The higher the plasma levels of HDL, the more efficient is the transport to the liver of excess cholesterol from peripheral cells.


Cholesteryl Ester Transfer Protein Reverse Cholesterol Transport Tangier Disease Premature Cardiovascular Disease Cholesteryl Ester Transfer Protein Gene 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989, 79:8–15.Google Scholar
  2. 2.
    Gordon DJ, Rifkind BM: High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989, 321: 1311–1316.PubMedCrossRefGoogle Scholar
  3. Gofman JW, Lindgren F, Elliot H, et al.: The role of lipids and lipoproteins in atherosclerosis. Science 1950, 111:166–186.Google Scholar
  4. Gofman JW, deLalla O, Glazier F, et al.: The serum lipid transport system in health, metabolic disorders, atherosclerosis, and coronary artery disease. Plasma 1954, 2:413–484.Google Scholar
  5. 5.
    Barr DP, Russ EM, Eder HA: Protein-lipid relationship in human plasma. II. In atherosclerosis and related conditions. Am J Med 1951, 11: 480–493.PubMedCrossRefGoogle Scholar
  6. 6.
    Miller GJ, Miller NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975, 1: 16–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976, 294: 293–298.PubMedCrossRefGoogle Scholar
  8. Gordon T, Castelli WP, Hjortland MC, et al.: High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977, 62:707–714.Google Scholar
  9. 9.
    Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromso heart-study: high-density lipoproteins and coronary heart-disease: a prospective case-control study. Lancet 1977, 1: 965–968.PubMedCrossRefGoogle Scholar
  10. Glomset JA, Janssen ET, Kennedy R, et al.: Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 1966, 7:638–648.Google Scholar
  11. 11.
    Brewer HB Jr, Santamarina-Fojo S, Hoeg JM: The molecular biology of the human plasma apolipoproteinemia, lipoprotein receptors, and lipoprotein lipase. In Primary Hyperlipoproteinemias. Edited by Steiner G, Shafrir E. New York: McGraw-Hill, Inc.; 1990: 43–74.Google Scholar
  12. 12.
    Breslow JL: Familial disorders of high-density lipoprotein metabolism. In The Metabolic and Molecular Bases of Inherited Disease. Edited by Scriver CR, Beaudet AL, Sly WS, et al. New York: McGraw-Hill, Inc.; 1995: 2031–2052.Google Scholar
  13. Menotti A, Keys A, Aravanis C, et al.: Seven Countries Study. First 20-year mortality data in 12 cohorts of six countries. Ann Med 1989, 21:175–179.Google Scholar
  14. 14.
    Keys A: High density lipoprotein cholesterol and longevity.I Epidemiol Community Health 1987, 42: 60–65.CrossRefGoogle Scholar
  15. 15.
    Pomerantz KB, Fleisher LN, Tall AR, Cannon P: Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin 12 synthesis. J Lipid Res 1985, 26: 1269–1276.PubMedGoogle Scholar
  16. Fleisher LN, Tall AR, Witte LD, et al.: Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982, 257:6653–6655.Google Scholar
  17. Steinbrecher UP, Parthasarathy S, Leake DS, et al.: Modification of low density lipoprotein by endothelial cells involves lipid perioxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984, 81:3883–3887.Google Scholar
  18. 18.
    Writing Group of the Histiocyte Society: Histiocytosis syndromes in children. Lancet 1987, 1: 208–209.Google Scholar
  19. 19.
    Parthasarathy S, Fong LG, Otero D, Steinberg D: Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci USA 1987, 84: 537–540.PubMedCrossRefGoogle Scholar
  20. 20.
    Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044: 275–283.PubMedCrossRefGoogle Scholar
  21. 21.
    Brewer HB, Jr, Santamarina-Fojo S, Hoeg JM: Molecular biology of the lipoproteins and the apolipoproteins and their role in atherosclerosis. In Molecular Basis of Cardiology. Edited by Roberts R. Boston: Blackwell Scientific Publishers; 1992: 415–441.Google Scholar
  22. Segrest JP, Jones MK, De Loof H, et al.: The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992, 33:141–166.Google Scholar
  23. Segrest JP, Garber DW, Brouillette CG, et al.: The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994, 45:303–369.Google Scholar
  24. Acton S, Rigotti A, Landschulz KT et al.: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518–520.Google Scholar
  25. Murao K, Terpstra V, Green SR et al.: Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 1997, 272:17551–17557.Google Scholar
  26. Landschulz KT, Pathak RK, Rigotti A et al.: Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996, 98:984–995.Google Scholar
  27. 27.
    Tall AR: Metabolic and genetic control of HDL cholesterol levels. J Intern Med 1992, 231: 661–668.PubMedCrossRefGoogle Scholar
  28. 28.
    Scanu AM, Fless GM: Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990, 85: 1709–1715.PubMedCrossRefGoogle Scholar
  29. Rader DJ, Schaefer JR, Lohse P, et al.: Increased production of apolipoprotein A-I associated with elevated plasma levels of high-density lipoproteins, apolipoprotein A-I, and lipoprotein A-I in a patient with familial hyperalphalipoproteinemia. Metabolism 1993, 42:1492–1434.Google Scholar
  30. Ikewaki K, Rader DJ, Sakamoto T, et al.: Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human choles-teryl ester transfer protein deficiency. / Clin Invest 1993, 92:1650–1658.Google Scholar
  31. 31.
    Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 1993, 34: 1255–1274.PubMedGoogle Scholar
  32. Yamashita S, Ishigami M, Arai T, et al.: Very high density lipoproteins induced by plasma cholesteryl ester transfer protein (CETP) have a potent antiatherogenic function. Ann NY Acad Sci 1995, 748:606–608.Google Scholar
  33. 33.
    Tall AR: An overview of reverse cholesterol transport. Eur Heart 1998,19A31–A3 5.Google Scholar
  34. 34.
    Ng DS, Leiter LA, Vezina C, et al: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994, 93: 223–229.PubMedCrossRefGoogle Scholar
  35. Lackner KJ, Dieplinger H, Nowicka G, et al.: High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest 1993, 92:2262–2273.Google Scholar
  36. Bekaert ED, Alaupovic P, Knight-Gibson CS, et al.: Characterization of apo A- and apo B-containing lipoprotein particles in a variant of familial apo A-I deficiency with planar xanthoma: the metabolic significance of LP-A-II particles. J Lipid Res 1991,32:1587–1599.Google Scholar
  37. 37.
    Sherman JL, Citrin C, Johns T et al: Erdheim-Chester disease: computed tomography in two cases. Am J Neuroradiol 1985, 6: 444–445.PubMedGoogle Scholar
  38. 38.
    Ordovas JM, Cassidy DK, Civeira F, et al: Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989, 264: 16339–16342.PubMedGoogle Scholar
  39. 39.
    Genest JJ Jr, Martin-Munley SS, McNamara JR, et al: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85: 2025–2033.PubMedCrossRefGoogle Scholar
  40. Schaefer EJ, Blum CB, Levy RI, et al.: Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N Engl J Med 1978, 299:905–910.Google Scholar
  41. 41.
    Schaefer EJ, Zech LA, Schwartz DE, Brewer H, Jr: Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980, 93: 261–266.PubMedCrossRefGoogle Scholar
  42. 42.
    Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994, 107: 85–98.PubMedCrossRefGoogle Scholar
  43. Rader DJ, Ikewaki K, Duverger N, et al.: Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993, 342:1455–1458.Google Scholar
  44. 44.
    Krauss RM: Regulation of high density lipoprotein levels. Med Clin North Am 1982, 66:403–30.Google Scholar
  45. 45.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary artery disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Study Group. N Engl J Med 1999, 341:41018.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • H. Bryan BrewerJr.

There are no affiliations available

Personalised recommendations